Kiniksa Announces 28-Day Clinical Outcomes Data from Mavrilimumab Treatment Protocol in Severe COVID-19 Pneumonia and Active U.S. IND for Phase 2/3 Clinical Trial

Suma Ramadas, PhD
Medical Affairs

Bud Bilanich
Success Coach

Liz Kane
Impactful Strategy

Matt Turner
Patient Affordability

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Matthew Durham
Omnidynamic Marketing

Amy Giles
Increasing Engagement

David Linetsky
Point-of-Care Marketing

Frank Burrell
Scientific Storytelling

Joey Cohen
Medication Adherence

Brenda Snow
Authentic Patient Voice

Stacey Gandler
Brand Nourishment

Pat Purcell
Meeting Engagement